Risk of stroke/systemic embolism, major bleeding and associated costs in non‐valvular atrial fibrillation patients who initiated apixaban, dabigatran, or rivaroxaban compared with warfarin in the US Medicare population

Abstract Objective: To compare the risk and cost of stroke/systemic embolism (SE) and major bleeding between each direct oral anticoagulant (DOAC) and warfarin among non-valvular atrial fibrillation (NVAF) patients. Methods: Patients (≥65 years) initiating...

Effectiveness and safety of apixaban versus warfarin in non‐valvular atrial fibrillation patients in “real‐world” clinical practice: A propensity matched analysis of 76,940 patients

Abstract The ARISTOTLE trial showed a risk reduction of stroke/systemic embolism (SE) and major bleeding in non-valvular atrial fibrillation (NVAF) patients treated with apixaban compared to warfarin. This retrospective study used four large US claims databases...